Hepatology · Article 184

When Can Hepatitis B Antiviral Therapy Be Stopped?

Hepatitis B treatment stopping requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Hepatitis B treatment stopping clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

Hepatitis B treatment stopping: practical clinical approach

This page focuses on Hepatitis B treatment stopping with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Hepatitis B treatment stopping

Clinical takeaway: For Hepatitis B treatment stopping, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: For most HBeAg-negative adults on long-term nucleos(t)ide analogue therapy, the 2025 AASLD/IDSA guideline suggests not withdrawing treatment until HBsAg loss. Functional cure—HBsAg loss with durable off-treatment viral suppression—is the preferred stopping landmark. Selected noncirrhotic patients who strongly desire discontinuation may be considered only with strict criteria, informed consent and intensive monitoring because virologic relapse and ALT flares are common. Therapy should not be stopped casually in cirrhosis.

Why stopping is difficult

Nucleos(t)ide analogues suppress reverse transcription but do not eliminate cccDNA, so viral rebound is common after withdrawal.

HBsAg loss changes the equation

HBsAg loss is the most reliable marker of functional cure and substantially lowers relapse risk.

Monitoring after withdrawal must be intensive

HBV DNA and ALT can rebound rapidly; some patients require prompt retreatment.

Practical clinical algorithm

1. Confirm whether HBsAg loss has occurred.

2. Do not stop treatment routinely in cirrhosis.

3. If stopping without HBsAg loss is considered, restrict to carefully selected noncirrhotic patients.

4. Discuss relapse, flare and retreatment risk explicitly.

5. Arrange frequent ALT/HBV DNA monitoring after withdrawal.

6. Restart promptly for clinically important relapse or hepatic dysfunction.

Common mistakes to avoid

Stopping because HBV DNA has been undetectable for one year.
Stopping in a patient who cannot comply with follow-up.
Assuming HBeAg seroconversion equals permanent cure.
Stopping cirrhotic patients casually.
Failing to monitor for months after withdrawal.

Trainee takeaway

HBV suppression is not eradication; for most patients, HBsAg loss remains the safest stopping landmark.

Frequently asked questions

Does undetectable HBV DNA mean cure?

No.

Can some noncirrhotic patients stop before HBsAg loss?

Selected patients can be considered under expert monitoring, but relapse is common.

How long should monitoring continue?

Close monitoring is essential for at least the early months and generally continues long term.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015.

2. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

3. Ghany MG, Pan CQ, Lok AS, et al. AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B. Hepatology. 2026;83:974-997. doi:10.1097/HEP.0000000000001549.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions